Lyxiga

Lyxiga is a prescription medication used to treat rheumatoid arthritis (RA) and psoriatic arthritis (PsA). It is a selective inhibitor of Janus kinase (JAK) 1, which is a protein involved in the inflammatory response. By inhibiting JAK1, Lyxiga helps to reduce inflammation and improve symptoms in patients with RA and PsA.

Lyxiga is available in tablet form and is typically taken once daily. It is usually prescribed in combination with other medications, such as methotrexate, to achieve optimal results. The most common side effects of Lyxiga include upper respiratory tract infections, nasopharyngitis, and headache. Serious side effects are rare but can include an increased risk of infections, lymphoma, and other serious infections.

Lyxiga was approved by the U.S. Food and Drug Administration (FDA) in 2016 and is marketed under the brand name Tofacitinib. It is manufactured by Bristol-Myers Squibb. Lyxiga is not approved for use in children or pregnant women. Patients should discuss the potential risks and benefits of Lyxiga with their healthcare provider before starting treatment.